Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098527 · ClinicalTrials.gov registry record · Phase 2
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00098527: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00098527 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00098527, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. FR901228 may also stop the growth of tumor cells by blocking some of the enzymes needed for their growth.
Interventions
- OTHER laboratory biomarker analysis
- DRUG romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098527
The ClinicalTrials.gov registry entry for NCT00098527 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00098527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098527 about?
NCT00098527 is a clinical study titled "FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer". This phase II trial is studying how well FR901228 works in treating patients with refractory stomach cancer or gastroesophageal junction. Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from divid...
What is the current status of trial NCT00098527?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00098527?
The interventions under investigation include: laboratory biomarker analysis (OTHER), romidepsin (DRUG).
Who is sponsoring clinical trial NCT00098527?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.